Loading... TH17 Genome-wide association studies have linked the T helper 17 (TH17) cell pathway to multiple autoimmune diseases. TH17 cells are potent inducers of tissue inflammation and have been implicated in the pathogenesis of many autoimmune diseases and human inflammatory conditions. Therapeutic interventions with inhibitors of components of this pathway – such as inhibitors of interleukin (IL-)23, IL-17, and the IL-17 receptor – have shown strong clinical benefit in immune disorders such as psoriasis, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Lead Pharma has identified a therapeutic target in the TH17 pathway that remains clinically unaddressed. The relevance of this target in TH17 biology has been validated in human immune cells and in pre-clinical in vivo models, as well as in genetic and patient databases. Back to pipeline RORγt ERRα LXR PRMT5 TH17 © Scicomvisuals | Privacy | Disclaimer

Loading... Who we are Lead Pharma is a clinical-stage pharmaceutical research & development company. We design and develop innovative small-molecule therapies to treat autoimmune diseases and cancer. Our team of R&D professionals offers a wealth of experience in numerous areas of drug discovery, from target identification through lead optimization to pre-clinical development. We have a proven track record of discovering, designing, and delivering pre-clinical and clinical stage candidate drugs. Our ambition Our ambition is to develop life-changing treatments for patients. For patients with cancer, our therapies target primary tumors, metastasis, treatment resistance, refractory tumors, and tumors for which the only treatment option is chemotherapy. For patients with autoimmune diseases, we aim to improve the lives of patients suffering from debilitating diseases, with a focus on oral therapies that have good efficacy and a clean safety profile. Our science Lead Pharma’s strengths in innovation rely on a powerful discovery engine that is based on comprehensive in-house capabilities and an integrated suite of cutting-edge technologies. Read more Our pipeline We are developing a pipeline of small-molecule drugs to treat autoimmune diseases and cancer. Read more Partnering Collaborations are a key part of our business strategy and we are actively seeking companies who are interested in forming new partnerships. Read more © Scicomvisuals | Privacy | Disclaimer